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ABSTRACT 
Objective: Human fetuin/2HS-glycoprotein (AHSG) is synthesized by 
hepatocytes. We intended to determine whether liver dysfunction or acute 
phase reaction is dominant in the regulation of its serum concentrations and to 
see if decreased AHGS levels are associated with short-term mortality. Design: 
We determined the serum AHSG levels in patients with acute alcoholic, acute 
A, B, and Epstein-Barr virus hepatitis, alcoholic cirrhosis, and hepatocellular 
cancer and correlated them to conventional laboratory parameters of 
inflammation and liver function. Patients were followed for one month. 
Methods: Serum AHSG was determined by radial immunodiffusion. Results: 
Compared to controls, significantly lower levels were found in patients with liver 
cirrhosis and hepatocellular cancer but not the acute viral hepatitides. Strong 
positive correlation with serum transferrin, albumin, prothrombin was found. 
Febrile episodes were not associated with significantly decreased AHSG levels. 
Concentrations below 300 g/ml were associated with high mortality rate 
(52.0%, relative risk: 5.497, 95% C.I.: 2.472-12.23, p<0.0001). Of all laboratory 
parameters studied serum AHSG levels showed the greatest difference 
between deceased and survived patients with cirrhosis and cancer. Moreover, 
other acute phase reactants did not differ significantly. The multiple logistic 
regression analysis indicated that the decrease of serum AHSG patients is 
independent from all other variables that were found decreased in deceased 
patients. Conclusions: Decreased serum AHSG concentration is due rather to 
hepatocellular dysfunction than the acute phase reaction and is an outstanding 
predictor of short-term mortality in patients with liver cirrhosis and liver cancer. 
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INTRODUCTION 
Human fetuin/2HS-glycoprotein (AHSG) is a glycoprotein found in the serum 
at a mean concentration of 600 g/ml. AHSG is known to behave as a negative 
acute phase reactant [1]. It accumulates in bone tissue and it has been 
postulated that the protein prevents untoward calcification [2, 3]. AHSG is 
expressed in several tissues of the embryo [4]. In adults, however, this protein 
is synthesized only by hepatocytes [5]. AHSG has been found to be the natural 
antagonist of several growth factors, i.e. insulin, transforming growth factor- 
(TGF-), epidermal growth factor (EGF), and hepatocyte growth factor/scatter 
factor (HGF/SF) [6, 7, 8], and is an inhibitor of the lymphocyte mitogenic 
response [9]. The regulatory role of AHSG in tissue regeneration has also been 
postulated [6]. 
Reduced levels of the negative acute phase reactants transferrin and 
albumin have been found in patients with cirrhosis and other alcoholic liver 
diseases [10]. Serum levels of AHSG have been found reduced in alcoholic 
cirrhosis and fatty liver [11]. These observations and ours on decreased levels 
of AHSG in primary biliary cirrhosis [12] have prompted us to investigate serum 
AHSG levels in acute viral hepatitides and liver cancer. By correlating serum 
AHSG levels to conventional laboratory parameters of liver disease we tried to 
determine whether decreases of AHSG levels reflect the acute phase reaction 
or the limited protein synthetic capacity of the liver. Since both processes result 
in decreased AHSG levels in serum, we also intended to delineate the 
usefulness of AHSG determinations in short-term follow-up and prognosis of 
liver diseases. 
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PATIENTS AND METHODS 
Patients 
The patients enrolled in the study gave informed consent approved by the local 
Ethical Committee. Their most important data are listed in Table 1. Serum 
samples of 51 healthy blood donors were used as control. Patients were 
followed for a 1-month period by blood sampling every 10 days. Besides history 
and appropriate clinical findings the diagnosis of the subsequent liver diseases 
was set up as follows: acute A hepatitis: anti-hepatitis A virus (HAV) IgM; acute 
B hepatitis: anti-hepatitis B virus (HBV) core antigen (HBc) IgM; acute Epstein-
Barr virus (EBV) hepatitis: anti-EBV IgM; liver cirrhosis: liver scan, abdominal 
ultrasonography; hepatocellular cancer: ultrasonography, computer 
tomography, liver biopsy. We found no correlations between age and serum 
AHSG concentrations neither in healthy controls nor in patients with any liver 
disease separately or combined. 
 
 
Determination of AHSG concentration 
Serum levels of AHSG were determined by radial immunodiffusion (RID) using 
10x10 cm slides. Five l of patient’s sera diluted to 1:4 was applied in 11.5 ml 
of Litex agarose gel (Sigma). Serum samples (1:4 dilution) with known 
concentrations of AHSG served as standards. The incubation was done at 
room temperature for 48 hours. We used two types of antibodies against AHSG 
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as the protein is synthesized is a single chain and is rapidly converted to a 
dipeptide form following the cleavage of a connecting peptide. The 
commercially available product (anti-AHSG, IgG fraction, Incstar, Cat No. 
81931, 13.7 mg/ml, in a final concentration of 84 l/11.5 ml gel) recognizes the 
dipeptide form. The other type of antibody binding to the newly synthesized 
single chain form of AHSG, was raised by immunizing a rabbit with recombinant 
human protein (final concentration of 568 l/11.5 ml gel). There was a strong 
correlation between data produced by the two assays both in healthy controls 
and patients. 
 
Production of anti-human AHSG antibodies 
Human recombinant AHSG was produced in the baculovirus expression vector 
system and purified from the supernatant of the Sf9 cells as described 
elsewhere [8,13]. One hundred g of purified AHSG was injected 
subcutaneously in a rabbit with complete Freund’s adjuvant. The injection was 
repeated twice at 14 days’ intervals using incomplete Freund’s adjuvant. 
Thereafter the rabbit was bled and the serum was pooled and stored at -20 C 
until further use. The AHSG binding capacity of the rabbit serum was confirmed 
by competitive ELISA. 
  
Other laboratory measurements 
The determination of the erythrocyte sedimentation rate (ESR), hematocrit, 
hemoglobin, white blood cell (WBC), granulocyte and thrombocyte count, 
serum bilirubin, serum aspartate aminotransferase (ASAT), alanine 
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aminotransferase (ALAT), serum alkaline phosphatase, -glutamyl 
transpeptidase (GT), prothrombin activities, total serum protein and albumin 
concentrations was performed using conventional standardized methods. 
Serum levels of 2-macroglobulin, transferrin, haptoglobin, and 1-acid 
glycoprotein were measured by RID. 
 
Statistical analysis 
Paired and unpaired data were analysed by the Wilcoxon and Mann-Whitney U 
tests, respectively. Correlation studies were done by the rank correlation 
analysis (Spearman). Contingency tables were analysed by the Fisher’s exact 
test. In the follow-up series, the first data of each patient was used in the 
comparison of groups and the correlation studies, respectively. The multiple 
logistic regression analysis was performed with the SPSS v.10.0 statistical 
program. The level of p < 0.01 was considered significant. 
 
 
RESULTS 
Serum AHSG concentrations of patients with liver disease 
The mean AHSG concentration in sera of patients with various liver diseases is 
shown in Figure 1. Patients with alcoholic cirrhosis and hepatocellular cancer 
had significantly lower AHSG levels than healthy subjects, whereas AHSG 
levels did not differ from controls in the acute A, B, and EBV hepatitis. Only 
data from disease groups with decreased AHSG concentration were analysed 
further. Since the sample size did not allow for separate statistical analysis in 
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patients with alcoholic cirrhosis and hepatocellular cancer, in part of evaluations 
data from these two groups were taken together. 
 
Correlation studies 
Serum AHSG levels were correlated to conventional laboratory parameters and 
to the concentration of some other serum glycoproteins. The serum AHSG 
concentration correlated positively with prothrombin, albumin, and transferrin 
levels (Table 2, column A). 
 
Serum AHSG levels fail to correlate with fever and infection 
We performed two types of calculations in order to estimate the effect of the 
acute phase reaction generated by fever and inflammation on serum AHSG 
levels. First, we compared the AHSG values of patients with and without fever 
at the time of enrolment. In cirrhosis patients, serum AHSG concentrations did 
not differ significantly between the febrile (381.5  39.1 g/ml mean ± SEM, n = 
33) and afebrile groups (413.2 ± 24.3 g/ml, n = 66, p = 0.5108). Second, 
individual patients were followed for episodes of intercurrent infections. These 
occurred in 5 patients with liver cirrhosis and in one patient with liver cancer and 
were proven by positive cultures for blood, sputum, or urine. Serum AHSG 
levels did not differ when secondary infections were present (371.0  24.7 
g/ml, mean ± SEM) or absent (447.8  62.8 g/ml, n = 6, p = 0.4375). 
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Serum AHSG levels and short-term mortality 
During the 1-month follow-up period, 23 out of 99 patients died: 19 patients with 
alcoholic cirrhosis, and 4 with hepatocellular cancer, respectively. Three 
patients died of intercurrent illnesses unrelated to liver disease, namely chronic 
pancreatitis, purulent meningitis, acute left ventricular failure. Only values of the 
remaining 20 patients, who were considered dying of liver failure, were 
analysed further. For comparison, a survivor group was formed from patients 
who survived the follow-up period and had the same liver disease as those in 
the deceased group. As Table 3A shows patients with AHSG concentrations 
constantly below 300 g/ml had a significantly higher risk of mortality than those 
with values above this level. 
 
Serum transferrin, prothrombin, and albumin levels and short-term mortality 
We made calculations regarding the risk of mortality for transferrin, as a strong 
correlation with this negative acute phase protein had been found in several 
disease groups. Only patients with transferrin levels below 124 mg/dl had 
higher but not statistically significant mortality rates associated with a high 
relative risk (Table 3B.). 
The comparison of the laboratory parameters of the deceased and survived 
groups is shown in column B of Table 2. Significant differences were found with 
hematocrit, WBC, granulocyte count, 2-macroglobulin. The AHSG values 
showed the strongest difference between the two groups - the difference in 
transferrin was much less pronounced. The deceased and survived groups 
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showed no statistical difference in prothrombin activity and serum albumin 
concentration whereas these parameters correlated with AHSG values strongly. 
Thus low serum AHSG levels were associated with short-term mortality 
of patients with liver cirrhosis and liver cancer. However, factors such as 
hematocrit or serum transferrin (with marginal significance) were also 
associated with the short-term mortality of the patients. Therefore, in order to 
adjust for the effect of these confounding variables, we have analysed the data 
by using multiple logistic regression (Table 4). When data were adjusted for 
age, gender, and the confounding variables enlisted above, a highly significant 
regression coefficient was found between AHSG levels and short-term 
mortality. This association was independent of the association between low 
hematocrit levels and mortality while no significant association was found in the 
case of other variables tested. When low AHSG levels were defined as  300 
g/ml (limit of the lowest quartile), according to logistic regression adjusted for 
the variables in Table 4, patients with low serum AHSG concentrations 
compared to those with normal AHSG had a 88.7 (95% C.I.: 3.4 – 2310, p = 
0.007) odds ratio to not survive 3 months after blood sampling. 
 
 
DISCUSSION 
Apart from a study in alcoholic cirrhosis and fatty liver [11] and our previous 
work on primary biliary cirrhosis [12] no other study has investigated serum 
AHSG levels in enough patients for statistical analysis in liver diseases. No 
correlation studies have been performed. In accordance with one study on 
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children hepatitis A [14] serum AHSG levels did not differ from controls in acute 
A, B and EBV hepatitis. Although each disease we have investigated is 
characterized by a considerable degree of liver cell dysfunction, low serum 
AHSG concentrations were detected only in the cirrhosis and hepatocellular 
cancer groups. Either acute phase reaction or decreased liver function or both 
can result in decreased serum concentration of AHSG. 
The role of the acute phase reaction is favoured by the strong positive 
correlation with transferrin levels. Proinflammatory cytokines such as interleukin 
(IL)-1, IL-6, tumour necrosis factor  (TNF) are known to induce the synthesis 
of the positive and down-regulate that of the negative acute phase reactants 
including AHSG in rat liver and human HepG2 cells [15, 16]. Their determinant 
role, however, can be questioned as elevated levels of these cytokines have 
been reported in patients with all diseases we have investigated, including 
acute hepatitis A [17], acute hepatitis B [18], hepatitis C [17, 19], acute hepatitis 
and liver failure [20, 21, 22]. The elevation of the serum concentration of the 
positive acute phase reactants is, however, often masked by the overall 
reduced protein synthesizing capacity in liver diseases [23]. Conversely, 
decreased level of the negative acute phase reactants would be expected to 
occur due to both inflammation and hepatocyte dysfunction and may serve as a 
good prognostic marker in liver diseases. The relationship between the levels of 
these cytokines and negative acute phase proteins has not been studied in 
clinical setting, nor has their effect on mortality in liver diseases. IL-6, however, 
has been found the strongest predictor of mortality in patients with end-stage 
kidney disease [24]. 
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On the other hand, several findings strongly argue against the major 
determinant role of the acute phase reaction and inflammation in regulation of 
AHSG levels in patients with liver diseases. First, we did not find inverse 
relationship with the positive acute phase reactants and several laboratory 
parameters of inflammation (ESR, WBC, granulocyte count). Second, serum 
AHSG was not markedly reduced further during febrile states or episodes of 
intercurrent infections, which was a common finding in bacterial sepsis, 
pneumonias and in infections occurring in haematological malignancies [1,25]. 
Third, serum AHSG levels correlated strongly and consistently with prothrombin 
activity, which is dependent solely on hepatocyte function. Although the positive 
correlation with albumin can be interpreted in both ways as this protein is also a 
negative acute phase reactant. In clinical practice, prothrombin and albumin 
levels are used as the best indicators of protein synthetic reserve in liver 
disease. 
We conclude that decreased serum AHSG levels indicate rather 
dysfunction of hepatocytes than an acute phase response. This concept has 
been supported by several observations. In patients with hepatitis C-related 
diseases elevated serum levels of IL-1, IL-6, and TNF correlated with 
prothrombin time better than with parameters of hepatic inflammation (ASAT 
and ALAT) [19]. In accordance with our observation a positive relationship 
between AHSG levels and the severity of alcoholic cirrhosis was found [11]. 
Similarly, serum IL-6 levels did not correlate to the gradual decrease of AHSG 
in advanced stages of primary biliary cirrhosis [12, 26]. 
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The regression studies suggest that hematocrit value may be almost as 
good as AHSG as a predictor of short-term mortality. Clearly, massive 
gastrointestinal bleeding was not a cause of death in our patients, mild 
microscopic bleeding, however, could not be ruled out. Since the aetiology of 
anaemia in these diseases is variable and is often independent of hepatocyte 
function low hematocrit levels cannot be regarded as good as AHSG in 
predicting short-term mortality in liver cirrhosis and hepatocellular cancer. In 
addition, red blood cell transfusion can also alter the haematological status 
independently from liver cell function. 
Our results suggest that at least at short-term, AHSG concentration has 
an outstanding predictivity of lethal outcome in patients with alcoholic cirrhosis 
and liver cancer even after adjustment to other confounding variables. In this 
respect AHSG was the best of all other laboratory parameters we studied. 
Compared to AHSG the alteration of transferrin concentration was much less 
pronounced and was associated with lower mortality rate and a slightly lower 
equal risk of fatal outcome. To our knowledge no other glycoprotein has been 
considered as short-term predictor of fatal outcome in liver disease. A longer 
follow-up is already under way. 
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Table 1. The number, age, and gender of patients 
 
 Number Gender 
Male/Fem
ale 
Age 
years, mean ± 
SD 
(min-max) 
Correlation 
with age* 
r (p) 
Acute viral hepatitis 
A 
50 37/13 28  10 (15-53) 0.0251 
(0.8625) 
Acute viral hepatitis 
B 
23 15/8 47  17 (20-80) 0.0077 
(0.9709) 
Acute EBV hepatitis 19 11/8 27  13 (15-68) 0.1603 
(0.5122) 
Liver cirrhosis  92 54/38 53  12 (28-88) -0.1138 
(0.2802) 
Hepatocellular 
cancer 
7 6/1 58  8 (50-71) 0.6724 
(0.1389) 
Healthy controls  51 27/24 47  6 (33-59) -0.1728 
(0.2253) 
 
n: number of observations; *: Spearman’s rank correlation coefficient; r: 
regression coefficient; p: value of significance. 
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Table 2. Correlation between serum fetuin/2HS-glycoprotein levels and 
laboratory parameters (A) and comparison of parameters of deceased and 
survived patients (B) with liver cirrhosis and hepatocellular cancer 
 
 A. 
Correlation 
with AHSG 
levels* 
B. 
Comparison of laboratory parameters in 
Deceased 
patients 
Survived patients  
Parameter n p n mean  SEM n mean  SEM p 
ESR 90 0.0980 11 52.8 ± 9.6 79 47.7 ± 3.3 0.5668 
Hematocrit 56 0.9627 9 0.29 ± 0.02 47 0.37 ± 0.01 0.0040 
Hemoglobin 56 0.8553 9 101.2 ± 6.5 47 121.4 ± 2.6 0.0435 
WBC 92 0.4224 13 11280 ± 1404 79 8266 ± 416 0.0505 
Granulocyte 
count 
53 0.5344 8 8788 ± 1653 45 6295 ± 552 0.2096 
Platelet count 88 0.1865 13 163.8 ± 38.3 76 191.7 ± 10.1 0.2723 
Serum bilirubin 96 0.0332 18 189.3  40.1 78 142.2  14.3 0.2278 
ASAT 97 0.8851 18 93.1  14.7 79 352.9  101.9 0.7772 
ALAT 95 0.8974 18 40.4  5.8 78 395.4  109.6 0.7927 
Serum alkaline 
phosphatase 
95 0.7873 18 481.1  85.8 77 325.1  26.1 0.0621 
GT 95 0.5129 18 380.2  124.8 77 361.4  66.4 0.7174 
Prothrombin 86 0.0003 13 53.9  6.3 73 65.5  2.5 0.2648 
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Total protein 83 0.1111 13 67.3  3.1 70 68.6  1.1 0.4907 
Albumin 83 0.0003 13 29.6  1.5 70 33.2  0.7 0.2465 
2-
macroglobulin 
62 0.1650 14 268.3  14.2 48 342.0  20.8 0.0180 
Transferrin 62 0.0024 14 150.1  13.6 48 194.9  10.1 0.0973 
Haptoglobin 59 0.5219 13 159.7  49.4 46 160.9  15.3 0.5462 
1-acid 
glycoprotein 
61 0.7232 14 97.8  14.3 47 90.9  4.8 0.9248 
AHSG   20 297.8 ± 29.6 79 459.0 ± 16.4 < 0.0001 
 
n: number of observations; *: Spearman’s rank correlation coefficient; p: value 
of significance. 
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Table 3. The mortality rates and relative risk of low serum levels of fetuin/2HS-
glycoprotein AHSG (A) and transferrin (B) in patients with liver disease 
 
A. 
AHSG concentration Died Survived Total Mortality rate 
(%) 
Below 300 g/ml 13 12 25 52.0 
Over 300 g/ml 7 67 74 9.5 
Total 20 79 99  
p < 0.0001, Relative Risk: 5.497, 95% C.I.: 2.472 – 12.23 
 
B. 
Transferrin 
concentration 
Died Survived Total Mortality rate 
(%) 
Below 124 mg/dl 6 10 16 37.5 
Over 124 mg/dl 8 38 46 17.4 
Total 14 48 62  
p = 0.1619, Relative Risk: 2.156, 95% C.I.: 0.8829 – 5.266 
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Table 4. Association of low fetuin/2HS-glycoprotein levels with short-term 
(within 3 months after blood sampling) mortality of patients with liver cirrhosis 
and liver cancer calculated by adjusted multiple logistic regression* 
 
Variable P value of regression coefficient* 
Age, years 0.4883 
Gender, male/female 0.5966 
Hematocrit 0.0095 
Granulocyte count 0.8497 
Transferrin,  124 mg/dl / > 124 mg/dl 0.1053 
AHSG  300 g/ml / > 300 g/ml 0.0070 
 
*adjusted for age, gender, and variables significantly associated with short-term 
mortality at univariate analysis (Table 2 column B). 
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Figure legend: 
 
Figure 1. Serum fetuin/2HS-glycoprotein concentration in patients with liver 
disease. 1: Healthy controls (n = 51), 2: Acute hepatitis A (n = 50), 3: Acute 
hepatitis B: (n = 23), Acute Epstein-Barr virus hepatitis (n = 19), 4: Alcoholic 
cirrhosis (n = 92), 5: Hepatocellular cancer (n = 7). *: p < 0.001. 
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